Bluejay Diagnostics (NASDAQ:BJDX) Shares Set to Reverse Split on Tuesday, November 3rd

Bluejay Diagnostics, Inc. (NASDAQ:BJDX)’s stock is set to reverse split before the market opens on Tuesday, November 3rd. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 2nd.

Bluejay Diagnostics Stock Down 4.7%

Shares of BJDX traded down $0.03 on Monday, hitting $0.53. The company’s stock had a trading volume of 181,513 shares, compared to its average volume of 2,220,212. The firm’s fifty day moving average price is $0.82 and its 200-day moving average price is $1.85. Bluejay Diagnostics has a fifty-two week low of $0.46 and a fifty-two week high of $7.92. The firm has a market capitalization of $2.37 million, a price-to-earnings ratio of -0.07 and a beta of 0.93.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BJDX. Wall Street Zen cut Bluejay Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, September 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer.

Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.

Bluejay Diagnostics is headquartered in Acton, Massachusetts, and serves the healthcare market through the development of diagnostic products for hospitals, clinics and other point-of-care environments.